Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C2733
http://purl.obolibrary.org/obo/NCIT_C2733
Preferred Name

Nimotuzumab
Definitions
A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.
label
Nimotuzumab
prefLabel
Nimotuzumab
Legacy Concept Name
TheraCim_hR3
in_subset
Preferred_Name
Nimotuzumab
Is_Value_For_GDC_Property
Display_Name
Nimotuzumab
Maps_To
Nimotuzumab
PDQ_Open_Trial_Search_ID
507582
UMLS_CUI
C1570482
FDA_UNII_Code
6NS400BXKH
prefixIRI
NCIT:C2733
Accepted_Therapeutic_Use_For
Glioma
NCI_Drug_Dictionary_ID
507582
Contributing_Source
CTRP
FDA
subClassOf
code
C2733
type
ALT_DEFINITION
A monoclonal antibody being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Nimotuzumab binds the epidermal growth factor receptor (EGFR) and blocks cancer cells that depend on epidermal growth factor for growth.
PDQ_Closed_Trial_Search_ID
507582
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
CAS_Registry
828933-51-3
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display